RxSight (RXST) to Release Quarterly Earnings on Thursday

RxSight (NASDAQ:RXST) is projected to issue its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect the company to announce earnings of ($0.19) per share and revenue of $25.63 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Wednesday, November 5, 2025 at 4:30 PM ET.

RxSight (NASDAQ:RXST) last released its earnings results on Thursday, August 7th. The company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.04) by ($0.04). The business had revenue of $33.64 million for the quarter, compared to analysts’ expectations of $39.78 million. RxSight had a negative net margin of 21.93% and a negative return on equity of 11.56%. The business’s quarterly revenue was down 3.7% compared to the same quarter last year. During the same quarter last year, the company posted ($0.16) earnings per share. On average, analysts expect RxSight to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

RxSight Trading Up 3.7%

RxSight stock opened at $9.00 on Wednesday. The stock has a market cap of $368.24 million, a P/E ratio of -11.25 and a beta of 1.16. The stock has a 50 day moving average of $8.79 and a 200-day moving average of $10.84. RxSight has a 52 week low of $6.32 and a 52 week high of $55.57.

Institutional Investors Weigh In On RxSight

Several institutional investors and hedge funds have recently made changes to their positions in RXST. Raymond James Financial Inc. acquired a new stake in RxSight in the second quarter worth $28,000. Tower Research Capital LLC TRC increased its position in RxSight by 156.2% in the second quarter. Tower Research Capital LLC TRC now owns 5,574 shares of the company’s stock worth $72,000 after buying an additional 3,398 shares during the period. Russell Investments Group Ltd. increased its position in RxSight by 112.3% in the second quarter. Russell Investments Group Ltd. now owns 8,684 shares of the company’s stock worth $113,000 after buying an additional 4,593 shares during the period. Osaic Holdings Inc. increased its position in RxSight by 1,417.0% in the second quarter. Osaic Holdings Inc. now owns 9,572 shares of the company’s stock worth $124,000 after buying an additional 8,941 shares during the period. Finally, WINTON GROUP Ltd acquired a new stake in RxSight in the second quarter worth $154,000. 78.78% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities analysts have recently commented on RXST shares. Needham & Company LLC reduced their target price on RxSight from $22.00 to $11.00 and set a “buy” rating for the company in a research note on Friday, August 8th. Zacks Research upgraded RxSight from a “strong sell” rating to a “hold” rating in a research note on Monday, September 8th. Bank of America reduced their target price on RxSight from $18.00 to $9.00 and set an “underperform” rating for the company in a research note on Wednesday, July 9th. Piper Sandler reduced their target price on RxSight from $18.00 to $10.00 and set a “neutral” rating for the company in a research note on Wednesday, July 9th. Finally, Jefferies Financial Group reissued a “hold” rating and set a $9.00 price target (down from $24.00) on shares of RxSight in a research report on Thursday, July 10th. One investment analyst has rated the stock with a Buy rating, nine have issued a Hold rating and three have issued a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Reduce” and a consensus target price of $10.00.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.